ZIM Laboratories has received permission from the Indian Central Drugs Standard Control Organization (CDSCO) for its novel Fixed Dose Combination formulation: Naproxen Delayed Release and Esomeprazole Capsules (375 mg/500 mg + 20 mg/20 mg). This product has been developed using ZIM’s proprietary drug delivery systems, comprising Naproxen Delayed-Release Minitablets, and Esomeprazole Pellets, filled together in a single hard gelatin capsule offering a differentiated and patient-friendly delivery platform and is part of its New Innovative Product (NIP) pipeline.
This approval strengthens ZIM’s presence in the pain management and gastro-protective therapeutic areas. ZIM has already signed a commercial supply agreement with an Indian pharmaceutical company for this product and is working toward commercial launch in India in FY 2026-27 (FY27). The approval also reinforces ZIM’s strategy of developing innovative, differentiated generics leveraging advanced formulation technologies.
ZIM Laboratories manufactures, formulates, and distributes drug delivery systems to develop generic pharmaceutical products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1659.30 |
| Dr. Reddys Lab | 1230.25 |
| Cipla | 1211.55 |
| Zydus Lifesciences | 923.60 |
| Lupin | 2324.15 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: